Keqin Qi
About
Keqin Qi is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Keqin Qi has authored 33 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 15 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Keqin Qi's work include Multiple Myeloma Research and Treatments (23 papers), Protein Degradation and Inhibitors (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Keqin Qi is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Protein Degradation and Inhibitors (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Keqin Qi collaborates with scholars based in United States, Spain and Belgium. Keqin Qi's co-authors include Brian Forsyth, John M. Leventhal, Katherine Chastain, Saad Z. Usmani, Edward A. Faber, Robert M. Rifkin, Don A. Stevens, Thomas S. Lin, Habte Yimer and Mohit Narang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Keqin Qi
29 papers receiving 345 citations
Peers
Keqin Qi
Ajay Major United States
Giacomo Loseto Italy
Sarah Côté United States
Lisa Madden United States
Cesar Rodriguez United States
Rebecca Karp Leaf United States
Eneida R. Nemecek United States
Colleen Lewis United States
Federica Cocito Italy
Citations per year, relative to Keqin Qi Keqin Qi (= 1×)
peers
Ajay Major
Countries citing papers authored by Keqin Qi
Since
Specialization
Citations
This map shows the geographic impact of Keqin Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keqin Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keqin Qi more than expected).
Fields of papers citing papers by Keqin Qi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Keqin Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keqin Qi. The network helps show where Keqin Qi may publish in the future.
Co-authorship network of co-authors of Keqin Qi
This figure shows the co-authorship network connecting the top 25 collaborators of Keqin Qi. A scholar is included among the top collaborators of Keqin Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keqin Qi. Keqin Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Popat, Rakesh, Alexa M. G. A. Laheij, Niels W.C.J. van de Donk, et al.. (2025). Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.. Journal of Clinical Oncology. 43(16_suppl).
2.
Costa, Luciano J., Nizar J. Bahlis, Saad Z. Usmani, et al.. (2024). Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235.
3.
Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S100.
4.
Garfall, Alfred L., Lotfi Benboubker, Katarina Uttervall, et al.. (2024). MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S549–S549.
5.
Delforge, Michel, María‐Victoria Mateos, Kristina Carlson, et al.. (2024). Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma. Blood. 144(Supplement 1). 7085–7085.
6.
Yong, Kwee, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. European Journal of Cancer. 215. 115157–115157.
7.
Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(2). 124–134.e5.
8.
Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S477–S477.
9.
Nooka, Ajay K., Cesar Rodriguez, María‐Victoria Mateos, et al.. (2023). Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. Cancer. 130(6). 886–900.
10.
Kater, Arnon P., Carol Moreno, Talha Munir, et al.. (2023). P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL. HemaSphere. 7(S3). e56748d2–e56748d2.
11.
Manier, Salomon, Ajay K. Nooka, Cesar Rodriguez, et al.. (2023). MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S480–S481.
12.
Krishnan, Amrita, Ajay K. Nooka, Ajai Chari, et al.. (2023). Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research. 12(6). e220186–e220186.
13.
Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2022). Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Leukemia & lymphoma. 63(10). 2383–2392.
14.
Weisel, Katja, Thomas G. Martin, Amrita Krishnan, et al.. (2021). Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clinical Drug Investigation. 42(1). 29–41.
15.
Martin, Thomas, Amrita Krishnan, Kwee Yong, et al.. (2021). Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 39(15_suppl). 8045–8045.
16.
Rao, Arpit, Howard I. Scher, Peter De Porre, et al.. (2020). Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. ESMO Open. 5(6). e000943–e000943.
17.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2019). Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. Blood. 134(Supplement_1). 1538–1538.
18.
Rifkin, Robert M., Jason M. Melear, Edward A. Faber, et al.. (2019). Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study. Blood. 134(Supplement_1). 863–863.
19.
Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2019). Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. British Journal of Haematology. 185(3). 492–502.
20.
Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2018). Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood. 132(Supplement 1). 152–152.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ajay Major Breakdown of academic impact, for papers by Giacomo Loseto Breakdown of academic impact, for papers by Sarah Côté Breakdown of academic impact, for papers by Lisa Madden Breakdown of academic impact, for papers by Cesar Rodriguez Breakdown of academic impact, for papers by Rebecca Karp Leaf Breakdown of academic impact, for papers by Eneida R. Nemecek Breakdown of academic impact, for papers by Colleen Lewis Breakdown of academic impact, for papers by Mazin Faisal Al‐Jadiry Breakdown of academic impact, for papers by Federica Cocito